Appearing as a promising advance in the fight against obesity, this medication is attracting considerable interest . This treatment combines effects of two known GLP-1 receptor agonists, liraglutide, plus an unique glucose-dependent incretin component. Preliminary patient results have shown significant fat reduction in patients with a high BMI … Read More